Can Plaquenil Cause Leukopenia?
Yes, Plaquenil (hydroxychloroquine) can cause leukopenia, though this is a rare hematologic adverse effect that requires monitoring during prolonged therapy.
Hematologic Toxicity Profile
The FDA drug label explicitly lists leukopenia among the blood and lymphatic system disorders associated with hydroxychloroquine, alongside other cytopenias including agranulocytosis, aplastic anemia, and thrombocytopenia 1. Periodic blood cell counts should be performed if patients are given prolonged therapy, and if any severe blood disorder such as leukopenia appears that is not attributable to the disease under treatment, discontinuation of Plaquenil should be considered 1.
Clinical Context and Monitoring
The 2012 American College of Chest Physicians guidelines note that antimalarial agents like hydroxychloroquine may cause hematologic effects, though the primary toxicity concerns focus on ocular, cardiac, and myopathic complications 2. The drug label emphasizes that antimalarial compounds should be used with caution in patients with blood disorders 1.
Monitoring Recommendations:
- Perform periodic complete blood counts during prolonged therapy 1
- Evaluate for severe blood disorders including leukopenia that cannot be attributed to the underlying disease
- Consider dose reduction in patients with hepatic or renal disease, as these conditions affect drug clearance and may increase toxicity risk 1
Important Caveats
The distinction between disease-related and drug-related leukopenia is critical. Many conditions treated with hydroxychloroquine (particularly systemic lupus erythematosus) commonly present with leukopenia as part of the disease itself. For example, in hairy cell leukemia patients, 39% present with absolute neutrophil counts <0.5 × 10⁹/L at baseline 3. Therefore, new or worsening leukopenia during hydroxychloroquine therapy requires careful assessment to determine whether it represents drug toxicity or disease progression.
Risk Factors for Hematologic Toxicity:
- Prolonged therapy duration
- Concurrent hepatic or renal disease (which increases drug levels) 1
- Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (primarily causes hemolysis rather than leukopenia) 1
- Concurrent use of other myelosuppressive medications
Clinical Action Points
If leukopenia develops during hydroxychloroquine therapy:
- Obtain complete blood count with differential to characterize the severity
- Assess whether leukopenia is attributable to underlying disease activity versus drug effect
- Review concurrent medications that may contribute to myelosuppression
- Consider dose reduction or discontinuation if leukopenia is severe and not explained by disease activity 1
- Monitor more frequently until blood counts stabilize
The overall incidence of hydroxychloroquine-induced leukopenia is low compared to its more common adverse effects (retinopathy, cardiomyopathy, gastrointestinal symptoms), but vigilance through periodic monitoring remains essential for early detection 1.